Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$140.43 USD

140.43
286,898

+3.91 (2.86%)

Updated Aug 4, 2025 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

What's in Store for Penumbra (PEN) Stock in Q3 Earnings?

by Zacks Equity Research

Penumbra (PEN) is expected to gain from strong performance by its neuro and peripheral vascular arms in Q3.

    Zacks Equity Research

    Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?

    by Zacks Equity Research

    IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.

      Zacks Equity Research

      Will Invisalign Drive Align Technology's (ALGN) Q3 Earnings?

      by Zacks Equity Research

      Align Technology (ALGN) is poised to gain from strength in the Invisalign space in Q3.

        Zacks Equity Research

        Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

        by Zacks Equity Research

        We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.

          Zacks Equity Research

          Baxter International (BAX) Q3 Earnings: What's in Store?

          by Zacks Equity Research

          Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.

            Zacks Equity Research

            Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?

            by Zacks Equity Research

            Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.

              Zacks Equity Research

              Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?

              by Zacks Equity Research

              Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.

                Zacks Equity Research

                Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?

                by Zacks Equity Research

                Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.

                  Zacks Equity Research

                  Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

                  by Zacks Equity Research

                  Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

                    Zacks Equity Research

                    Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?

                    by Zacks Equity Research

                    Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.

                      Zacks Equity Research

                      What to Expect From Thermo Fisher (TMO) in Q3 Earnings

                      by Zacks Equity Research

                      Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.

                        Zacks Equity Research

                        Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?

                        by Zacks Equity Research

                        We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.

                          Zacks Equity Research

                          Can CR Bard (BCR) Spring a Surprise This Earnings Season?

                          by Zacks Equity Research

                          We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

                            Zacks Equity Research

                            Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

                            by Zacks Equity Research

                            ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

                              Kevin Cook headshot

                              $200 Club Bullish Stampede

                              by Kevin Cook

                              These 5 growth stocks are leading the charge and keeping their promise to hit $200 sooner than even I imagined.

                                Kevin Cook headshot

                                Gaming the Stock Market with Poker Smarts

                                by Kevin Cook

                                Technical analysis and probability skills are essential, but behavioral analysis will take you to the pro's table.

                                  Zacks Equity Research

                                  Align Technology (ALGN) Prospects Bright, Competition Rife

                                  by Zacks Equity Research

                                  Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                                    Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard

                                      Zacks Equity Research

                                      Align Technology at 52-Week High: What's Driving the Stock?

                                      by Zacks Equity Research

                                      Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.

                                        Zacks Equity Research

                                        BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

                                        by Zacks Equity Research

                                        BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                          Zacks Equity Research

                                          Align Technology-Patterson Dental Deal Expands iTero Reach

                                          by Zacks Equity Research

                                          Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.

                                            Zacks Equity Research

                                            Align Technology's Invisalign Sales Strong Amid Margin Woes

                                            by Zacks Equity Research

                                            Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

                                              Zacks Equity Research

                                              Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                                              by Zacks Equity Research

                                              Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.

                                                Zacks Equity Research

                                                Quality Systems Professional Service a Drag, Competition Rife

                                                by Zacks Equity Research

                                                Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.

                                                  Zacks Equity Research

                                                  Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio

                                                  by Zacks Equity Research

                                                  Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.